Showing results (1-10 of 202) with videos related to
Sort By:
Pageof 21
Expert Review of Respiratory Medicine|October 9, 2019
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of responseMarco Caminati, Luca Cegolon, Andrea Vianello, et al.Expert Review of Respiratory Medicine|March 11, 2017
Non-opioid medications for the relief of chronic breathlessness: current evidenceCarlo Barbetta, David C Currow, Miriam J JohnsonIndian Journal of Occupational and Environmental Medicine|March 22, 2021
The Medical Concrete Cancer of the Lung: A Unique Case ReportMario Tamburrini, Unnati Desai, Umberto Zuccon, et al.Journal of Dietary Supplements|December 21, 2020
Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation?Davide Chesini Ms, Marco Caminati MdVaccines|January 14, 2021
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?Marco Caminati, Gabriella Guarnieri, Gianenrico SennaCurrent Opinion in Allergy and Clinical Immunology|November 6, 2019
Biologicals for severe asthma: what we can learn from real-life experiences?Diego Bagnasco, Marco Caminati, Giovanni PassalacquaCurrent Opinion in Allergy and Clinical Immunology|October 16, 2013
Safety and tolerability of sublingual immunotherapy in clinical trials and real lifeGianenrico Senna, Marco Caminati, Giorgio Walter CanonicaExpert Review of Clinical Immunology|September 25, 2019
What have recent advances in therapy taught us about severe asthma disease mechanisms?Marco Caminati, Brooke Polk, Lanny J RosenwasserImmunology and Allergy Clinics of North America|October 5, 2020
Biologics for the Treatment of Allergic Conditions: Eosinophil DisordersBianca Olivieri, Elisa Tinazzi, Marco Caminati, et al.Biologics : Targets & Therapy|June 14, 2019
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologicMarco Caminati, Diego Bagnasco, Rachele Vaia, et al.Pageof 21